Press Releases Chugai Pharmaceutical Co., Ltd.

Equities

4519

JP3519400000

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 06:30:00 18/02/2026 GMT			5-day change	1st Jan Change
9,400.00 ^JPY	+2.51%		+2.17%	+14.04%

02-06	Japan's Nikkei rallies on earnings in unsteady trade before Sunday election	RE
02-06	Japanese drugmakers slump after Trump unveils discount drug website	RE

Press Releases

02-09	Chugai Pharmaceutical : NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period	PU
01-30	Chugai Announces 2025 Full Year Results and Forecasts for 2026	AQ
01-30	Chugai Relocates Head Office	AQ
01-30	Chugai Pharmaceutical Co., Ltd. - Revision of the Stock Compensation System	AQ
01-29	Chugai Pharmaceutical : Full Year Results (Jan-Dec 2025)	PU
01-29	Chugai Pharmaceutical : Supplementary Materials Supplementary Materials	PU
01-28	Chugai Pharmaceutical : Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer	PU
01-28	Chugai Pharmaceutical : Preclinical Results of the Anti-CTLA-4 Switch Antibody ROSE12 Published in the Journal for ImmunoTherapy of Cancer	PU
01-15	Chugai Pharmaceutical : Presentation	PU
01-12	Chugai Receives Tokyo Governor Prize for Corporate Governance of the Year 2025	AQ
12-24	Chugai Pharmaceutical : Corporate Governance Report	PU
12-22	Chugai Pharmaceutical : Obtains Regulatory Approval for Tecentriq for the Additional Indication of Thymic Carcinoma, a Rare Disease	PU
12-18	Chugai Pharmaceutical : Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron	PU
12-17	Chugai Pharmaceutical : Awarded Highest A-Ratings by CDP in Climate Change and Water Security	PU
12-11	Chugai Pharmaceutical : Roche’s Announcement Regarding Giredestrant (Presentation of Latest Data in Estrogen Receptor Positive Breast Cancer at SABCS)	PU
12-11	Chugai Pharmaceutical : Opens U.S. Partnering Office in South San Francisco to Accelerate Global Open Innovation	PU
12-08	Chugai Pharmaceutical - 48-Week Phase III Results Presented at Japanese Retina and Vitreous Society Meeting Show that Vabysmo Sustained Vision Improvements in Japanese Patients with Angioid Streaks	AQ
12-08	Chugai Pharmaceutical : 48-Week Phase III Results Presented at Japanese Retina and Vitreous Society Meeting Show that Vabysmo Sustained Vision Improvements in Japanese Patients with Angioid Streaks	PU
11-26	Chugai Pharmaceutical : Renalys Pharma’s Announcement Regarding Sparsentan (Results of Domestic Phase III Study for IgA Nephropathy)	PU
11-25	Chugai Pharmaceutical : Port Delivery System with Ranibizumab Demonstrates Results Phase I/II Trial for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema in Japan	PU
11-20	Chugai Pharmaceutical : Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Repotrectinib with NTRK Fusion-Positive Solid-Tumors	PU
11-20	Chugai Pharmaceutical : Anti-Cancer Agent/Humanized Anti-CD20 Monoclonal Antibody Gazyva, Now Available for Use in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia	PU
11-19	Chugai Pharmaceutical : Roche’s Announcement Regarding giredestrant (Announcement of Phase III lidERA Study Results)	PU
31/10/25	Chugai Pharmaceutical Co., Ltd. - Roche Announces Global Phase III INShore Study Topline Results on Gazyva for Idiopathic Nephrotic Syndrome in Children and Young Adults	AQ
30/10/25	Chugai Pharmaceutical : Roche Announces Global Phase III INShore Study Topline Results on Gazyva for Idiopathic Nephrotic Syndrome in Children and Young Adults	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

MoU between Chugai, SoftBank and SB for joint research using generative AI

February 03, 2025 at 08:32 am